Ramius Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Ramius Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-338,042	Closed	-$5.94M	–	423
2021 Q3	$5.94M	Buy	+338,042	New	+$3.95M	3.54%	7

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Ramius Advisors's TRIL Position: Q4 2021 in Review

Ramius Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 338,042 shares — an estimated $5.94M sold.

Ramius Advisors first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $5.94M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Ramius Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Ramius Advisors sold 338,042 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $5.94M.
Ramius Advisors first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Ramius Advisors's Trillium Therapeutics Inc. position peaked at $5.94M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Ramius Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.